Skip to content
DataLookout
Menu

NCT07405606

Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 4 more changesShow less
    • Eligibility criteria expanded, about 27 words
    • Start date changed from estimate of Mar 2026 to Mar 23, 2026
    • Secondary endpoints: details revised at 12 of 12 entries
    • Site details revised
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Adherence
Timeframe: Week 2 (Visit 4)
Montgomery-Asberg Depression Rating Scale (MADRS)
Timeframe: Baseline; 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.
Hamilton Depression Rating Scale (HAMD-17)
Timeframe: 4-week post dose; week 26.
Quick Inventory of Depressive Symptomatology - Self Report (QUIDS-SR)
Timeframe: Baseline; 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.
Alcohol Timeline Followback (TLFB)
Timeframe: Baseline; week 2 (visit 3); 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.
Clinical Institute Withdrawal Assessment (CIWA)
Timeframe: Baseline; week 2 (visit 3); week 2 (visit 4); 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.
Prediction of Alcohol Withdrawal Severity Scale (PAWSS)
Timeframe: Baseline; 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.
Penn Alcohol Craving Scale (PACS)
Timeframe: Baseline; 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.
Addiction Severity Index (ASI)
Timeframe: Baseline; 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.

Secondary (12)

5 Dimensional Altered States of Consciousness (5-DASC)
Psychological Insight Questionnaire (PIQ)
Mystical Experience Questionnaire (MEQ)
Challenging Experience Questionnaire (CEQ)
General Anxiety Disorder-7th edition (GAD-7)
Show 7 moreShow less
State Trait Anxiety Index (STAI)
World Health Organization Quality of Life Questionnaire Brief Version (WHOQOL-BREF)
Big Five Inventory (BFI)
Pittsburgh Sleep Quality Index (PSQI)
Acceptance & Action Questionnaire II (AAQ-II)
Stanford Expectations of Treatment Scale (SETS)
Working Alliance Inventory (WAI)

Arms and interventions

Psilocybin (25 mg)Experimental

Participant is administered one oral capsule (25 mg psilocybin) with water.

PlaceboPlacebo comparator

Participant is administered one oral capsule (0 mg psilocybin) with water.

Drugs: Psilocybin 25 mg, Placebo

Sites

1 site in 1 country

  • Centre for Addiction and Mental HealthToronto, Ontario, Canada